Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer

Effective Pharmacotherapy
doi 10.33978/2307-3586-2019-15-38-14-18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medforum

Related search

Pcn163 - Cost-Effectiveness of Add-On Pertuzumab Combined With Trastuzumab and Docetaxel Versus Placebo as Treatment of Her-2 Positive Metastatic Breast Cancer in Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2018English

A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)

Breast Cancer Research
Cancer ResearchOncology
2019English

Comparison of the Efficacy and Survival Analysis of Neoadjuvant Chemotherapy for Her-2-Positive Breast Cancer

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Neoadjuvant Chemotherapy With Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results After a Median Follow-Up of Over 4 Years

Breast Care
SurgeryOncology
2016English

HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2004English

Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy